ArticlePatient related outcome measures2025
Perspectives on Intravenous Iron Therapy Logistics and Adherence: Results from a Patient Survey.
Article in Patient related outcome measures, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ferroportin at the Crossroads of Iron Biology: Disease, Regulation and Modulation.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Iron deficiency anemia (IDA) affects approximately 5 million people in the United States (US), significantly impacting quality of life (QoL) and overall health. Iron stores can be replenished through oral iron or, if ineffective/poorly tolerated, through intravenous iron (IVI) therapy. Despite IVI effectiveness, patients do delay/miss infusion appointments, leading to incomplete treatment response. Here we evaluated multiple-dose IVI therapy logistics and adherence from the patient perspective. Patients and Methods: US adult patients (≥18 years) with confirmed IDA who were currently prescribed an IVI treatment course were asked to respond to a 46-question online survey in early 2023. Questions covered patient demographics, appointment logistics, IVI infusion experience, impact of infusion on daily activities, reason(s) for missing any doses, and considerations for improving adherence. Results: A total of 323 patients completed the survey, 193 of whom were prescribed ≥2 IVI infusions per month. Of these patients, 71/193 (36.8%) reported missing at least one dose, despite its effectiveness at improving symptoms. Most patients (122/193 [64.3%]) agreed that multiple-dose IVI therapy adversely impacted their QoL by reducing their productivity (63.4%) and attendance at important events (64.8%), with 80.3% reporting having to schedule their life around therapy. A third of patients (73/193 [38.1%]) were unsatisfied with their infusion frequency, with most (163/193 [84.5%]) agreeing that fewer IVI infusions would improve adherence, and most also (174/193 [90.1%]) preferring a single-dose option if available. Conclusion: Time spent arranging and receiving multiple IVI infusions per month can interfere with patients' daily activities, leaving them dissatisfied with their IVI treatment experience. In this study, single-dose IVI infusions were a preferred option for patients with IDA, which may improve adherence to the complete course of treatment and offer improved QoL. Therefore, patient preference, convenience, and satisfaction should be considered and discussed when determining the type of IVI treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.